Molecular Weight(MW): 136.11
Allopurinol is a purine analog inhibitor of the enzyme xanthine oxidase, used to treat gout or kidney stones, and to decrease levels of uric acid.
Purity & Quality Control
Choose Selective ROS Inhibitors
|Description||Allopurinol is a purine analog inhibitor of the enzyme xanthine oxidase, used to treat gout or kidney stones, and to decrease levels of uric acid.|
Allopurinol reverses the increased xanthine oxidase activity in ischemia-reperfusion injury of neonatal rat hearts. Allopurinol (10 mM) treatment suppresses xanthine oxidase activity induced by hypoxia-reoxygenation injury and the production of reactive oxygen species. Allopurinol also decreases the concentration of intracellular Ca2+ increased by enhanced xanthine oxidase activity. 
|In vivo||Allopurinol shows abnormal pyrimidine metabolism together with renal toxicity which could be ameliorated by uridine, indicating that Allopurinol essentially causes pyrimidine metabolism abnormality leading to renal impairment in normal mice. Allopurinol increases urinary OD excretion to an extent similar to that in normal mice administered the same dose of Allopurinol in DNFB-sensitized mice.  Allopurinol promotes a clinical improvement which is accompanied by a reduction in the parasitic load in the blood, skin and lymph nodes but, even after long period of allopurinol administration alone, Leishmania may persist in dog tissues in Leishmania-infected dogs.  Allopurinol prevents early alcohol-induced liver injury in rats, most likely by preventing oxidant-dependent activation of NF-kappaB.  Allopurinol protects dose-dependently against acetaminophen-induced cell injury, the loss of ATP and the increase of the GSSG content in the total liver and in the mitochondrial compartment without inhibiting reactive metabolite formation in mice. Allopurinol almost completely inhibits hepatic xanthine oxidase and dehydrogenase activity, but only high doses prevents the increase of the mitochondrial GSSG content. |
-  Kang SM, et al. Eur J Pharmacol,?006, 535(1-3), 212-219.
-  Horiuchi H, et al. Life Sci,?000, 66(21), 2051-2070.
-  Manna L, et al. Vet J,?008, 177(2), 279-282.
|In vitro||DMSO||27 mg/mL (198.36 mM)|
|Water||4 mg/mL (29.38 mM)|
|Ethanol||3 mg/mL (22.04 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT00602693||Completed||Leukemia|Lymphoma|Multiple Myeloma|Plasma Cell Neoplasm|Myelodysplastic Syndromes||Masonic Cancer Center, University of Minnesota||July 23, 2007||Phase 1|
|NCT02661035||Not yet recruiting||Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Plasma Cell Leukemia|Myelodysplastic Syndromes|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|B-Cell Lymphoma|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Mantle-Cell Lymphoma|Prolymphocytic Leukemia|Lymphoblastic Lymphoma|Burkitts Lymphoma|Non-Hodgkins Lymphoma|Multiple Myeloma|Myeloproliferative Syndromes|Hematological Diseases||Masonic Cancer Center, University of Minnesota||March 2017||Phase 2|
|NCT03022747||Recruiting||Lymphoblastic Leukemia, Acute, Childhood||Vastra Gotaland Region||January 2017||Phase 2|
|NCT02956278||Recruiting||Chronic Gout|Hyperuricemia||University of California, San Francisco|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Open Medicine Institute||November 2016||Phase 4|
|NCT02579096||Not yet recruiting||Gout|Chronic Kidney Diseases||VA Office of Research and Development||November 2016||Phase 4|
|NCT02888054||Active, not recruiting||Healthy||Ardea Biosciences, Inc.||August 2016||Phase 1|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.